Fresenius Biopharma Arm Reaches 2030 Profitability Target Early
J.P. Morgan says Fresenius's biopharma operations have already reached the 20% adjusted EBIT margin target set for 2030, earlier than the bank's expected 2027–2028 timeframe.
J.P. Morgan says Fresenius's biopharma operations have already reached the 20% adjusted EBIT margin target set for 2030, earlier than the bank's expected 2027–2028 timeframe.